A Study to Explore Treatment Regimens and Clinical Outcomes of the NSCLC Patients With Different Dirver Genes
A Prospective Observational Study to Explore Treatment Regimens and Clinical Outcomes of the NSCLC Patients With Different Driver Genes
1 other identifier
observational
750
1 country
1
Brief Summary
A single-center, non-interventional prospective observational study in the NSCLC patients with different driver genes
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2018
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2018
CompletedFirst Submitted
Initial submission to the registry
July 10, 2018
CompletedFirst Posted
Study publicly available on registry
October 18, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2022
CompletedOctober 18, 2018
October 1, 2018
4.4 years
July 10, 2018
October 15, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Differences in overall survival rates
Differences in overall survival rates of the NSCLC patients with various gene types
2018-2022
Secondary Outcomes (7)
Interaction impact between gene types and treatment modalities or regimens on disease-free survivals
2018-2022
Statuses of clinical treatment regimens
2018-2022
Relevance of gene types
2018-2022
Relevance of overall survival rates and gene types
2018-2022
Impacts of disease-free survivals on gene types
2018-2022
- +2 more secondary outcomes
Study Arms (1)
NSCLC patients with driver genes
NSCLC patients and driver genes
Interventions
Eligibility Criteria
The pathologically diagnosed patients with non-small cell lung cancer who were performed with NGS technology
You may qualify if:
- The patients with lung cancer who were performed with next-generation sequencing (NGS) technology from 2015 to 2017;
- The patients who were at least 18 years;
- The pathologically diagnosed patients with non-small cell lung cancer (NSCLC)
You may not qualify if:
- None
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Wenhua of Liang
Guangzhou, Guangdong, 510120, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Wenhua Liang, Ph.D
The First Affiliated Hospital of Guangzhou Medical University
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
July 10, 2018
First Posted
October 18, 2018
Study Start
July 1, 2018
Primary Completion
December 1, 2022
Study Completion
December 1, 2022
Last Updated
October 18, 2018
Record last verified: 2018-10
Data Sharing
- IPD Sharing
- Will not share